Over the past few months, it’s likely that your patients with cancer have had important appointments canceled and/or delayed.
Navigating the backlog of visits may be challenging, especially when considering the uncertainty of disease progression and how it can affect treatment strategies or outcomes.
Genetic testing is recommended by professional guidelines for patients with breast, ovarian, endometrial, colorectal, pancreatic, and prostate cancers.
Results can reveal how quickly a cancer may progress; identify germline mutations that inform treatment or surgical intervention; and even qualify patients for clinical trials, allowing you to better stratify patients based on risk.
Our genetic tests offer customizable hereditary cancer panels that provide clear results.
Additionally, saliva tests can be mailed directly to patients, so they can submit a sample from the comfort and safety of home.
Gia, our HIPAA-compliant genetic information assistant, provides an end-to-end genetic testing framework that helps identify patients who could benefit from germline genetic testing.
After identifying patients, Gia facilitates patient education and answers questions about testing.
In-network for more than 300 million medically insured lives, Invitae also offers flat patient-pay rates for those not covered by insurance.
This allows more patients to benefit from genetic testing, without the hurdle of cost.